Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek.

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Ultragenyx Pharmaceuticals has announced the extension of approval by Health Canada for Evkeeza (evinacumab) for HoFH.

WHO’s director general described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.

Amid general supply chain disruption, scaling pharma businesses need expert logistics partners on hand to achieve growth.

Illimis has completed a Series B funding round, securing $42m for the development of its GAIA-based Alzheimer's disease therapeutics.